普罗布考联合厄贝沙坦治疗糖尿病肾病的疗效观察  

Observation on the Efficacy of Probucol Combined with Irbesartan for the Treatment of Diabetic Nephropathy

作　　者：李跃红[1] 陈健[1] 王清华[1] 何计南[1] 

机构地区：[1]湖南省娄底市中心医院肾内科,湖南娄底417000

出　　处：《医学临床研究》2012年第9期1731-1733,共3页Journal of Clinical Research

摘　　要：【目的】观察普罗布考联合厄贝沙坦治疗糖尿病肾病（DN）的疗效。【方法】60例DN患者随机分成治疗组和对照组。两组患者均在严格执行糖尿病饮食、减少蛋白摄入、控制血糖、血压达标的基础上，治疗组给厄贝沙坦150mg／d口服，同时给普罗布考每次0．5g，每天两次口服；对照组单用厄贝沙坦150mg／d口服。两组均随访3个月。【结果】两纽治疗后血清肌酐（Scr）、血丙二醛（MDA）、C反应蛋白（cRP）、尿白蛋白排泄率（UAER）均有降低（P〈0．05）；治疗组治疗后CRP和MDA、uAER较对照组明显下降（P〈0．05）。【结论】普罗布考与厄贝沙坦联合应用比单用厄贝沙坦能更有效地减轻蛋白尿和保护肾脏。[Objective] To observe the efficacy of probucol combined with irbesartan for treating diabetic nephropathy（DN）. [Methods]Sixty DN patients were randomly divided into treatment group and control group. Based on giving diabetic diet, reducing protein in diet, controlling blood glucose and blood pressure be- low the standard, irbesartan 150mg/d and probucol 0.5g per time were taken orally in treatment group and irbesartan 150mg/d was taken orally alone in control group. Two groups were followed up for 3 months. [Results]Serum creatinine（Scr）, malondialdehyde（MDA）, C reaction protein（CRP） and urinary album excretion rate（UAER） in two groups after treatment decreased（ P 〈0.05）. Compared with control group, MDA, CRP and UAER in treatment group decreased after treatment（ P 〈0.05）. [Conclusion] Probucol combined with irbesartan is more effective in reducing proteinuria and＇ protecting the kidney than irbesartan alone.

关 键 词：糖尿病肾病 药物疗法 普罗布可 投药和剂量 受体 血管紧张素 拮抗荆和抑制剂 

分 类 号：R692.39[医药卫生—泌尿科学]